)

Medigene (MDG1) investor relations material
Medigene Status Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Strategic refocus and organizational realignment
Medigene is prioritizing R&D programs with the highest potential return, focusing on MDG3010 with WuXi Biologics and pausing other autologous cell therapy programs while seeking partnerships for them.
A workforce reduction of 40% and other cost-saving measures are being implemented to align with the new R&D focus.
Financial guidance and cash runway remain unchanged, extending to July 2025, with €9.5M in cash as of September 30, 2024.
The company is open to evaluating acquisition offers and is actively seeking partnerships and financing to extend the runway into 2026 and beyond.
Organizational realignment supports sustainable growth and long-term success.
Pipeline and partnership updates
MDG3010, a bispecific TCR TCE program with WuXi Biologics, is the lead focus, with proof-of-principle data expected in H2 2025.
MDG1015, a 3rd generation TCR-T therapy, received IND approval in Q3 2024; CTA submission is planned for Q4 2024, but trial initiation is delayed pending financing or partnerships.
All other autologous cell therapy programs are paused, with efforts to find partners for further development.
The WuXi Biologics partnership is a 50/50 research and collaboration agreement until lead candidate development, after which economics may shift.
Partnerships with BioNTech, Regeneron, and WuXi Biologics validate the platform and provide milestone and royalty opportunities.
Market and financial context
Investor and partner sentiment currently favors non-cellular, antibody-based bispecific approaches over preclinical autologous TCR-T therapies.
The bispecific therapies market is projected to grow at a 40.9% CAGR to over $80 billion by 2030.
Medigene is seeking business development, M&A, and non-dilutive capital opportunities, but cannot comment on the maturity of ongoing discussions.
Share price is considered undervalued, with potential for improvement tied to business development or M&A activity.
Revenue sources include upfront, milestone, R&D payments, and product sales.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage